ANZCTR search results

The purpose of this study is to identify the time point of peak serum potassium levels during the reperfusion phase of adult liver transplantation. We aim to assess the the changes in blood potassium levels from baseline values during reperfusion, and evaluate clinical factors that may be associated with the development of hyperkalaemia. Who is it for? This is a retrospective study evaluating potassium levels in adult patients undergoing primary orthotropic liver transplantation. Study details The aim of this study is to quantify the changes in potassium during the reperfusion phase of liver transplantation. Elevated recipient serum potassium levels have been identified as an independent risk factor for post-operative mortality in liver transplantation. Further, severe hyperkalemia at reperfusion can result in cardiac arrhythmias and cardiac asystole if not adequately monitored and treated. We consider the incidence and severity of hyperkalaemia in this setting. In addition, we will highlight the importance of evaluating the changes in potassium relevant to patients undergoing liver transplantation. It is hoped that this study will be hypothesis generating and provide valuable data for power calculations for future studies on evaluating changes in potassium values during reperfusion. Further, we will provide an in-depth insight of the changes in serum potassium levels during the reperfusion stage to guide clinicians caring for such patients.

The overall goal of this project is to investigate the effectiveness of a universal, mental health and suicide prevention program – Youth Aware of Mental Health (YAM) – for reducing suicidal ideation and increasing help-seeking. The study will test the effectiveness of the YAM intervention for decreasing suicidal ideation from baseline to post-intervention and at 3-month follow-up compared to a waitlist control group.

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of both single and multiple oral doses of an already approved drug called etifoxine. This study will run in 2 stages and involve approximately 30 participants in total. Stage 1 will evaluate the pharmacokinetics, pharmacodynamics and safety of single doses of etifoxine. This stage will enrol approximately 12 participants into a crossover design study where they will receive either etifoxine as a single dose or a placebo at the first visit and then they will receive the opposite intervention at the next visit 7 days later. Stage 2 will evaluate the pharmacokinetics, pharmacodynamics and safety of multiple doses of etifoxine. This stage will enrol approximately 18 participants who will be randomised to receive either etifoxine or a placebo given every 12 hours for 7 days.

The primary aim of this study will be to determine if a pre-operative questionnaire, the ARISE tool, can predict discharge destination to home or inpatient rehabilitation following primary total knee replacement surgery. Existing tools have been criticised for not being predictive of "moderate" scorers, only predictive of those scoring in the high or low range categories. The ARISE tool is designed to capture additional information around a patient's beliefs rather than demographic features such as age and gender etc alone.

Friedreich ataxia (FA) is a chronic, progressive, and terminal illness. Currently, there are no effective treatments and no sensitive biometrics of illness progression for FA. Oxidative stress has been proposed as a candidate molecular process that contributes to the underlying neuropathology, and/or reflects the cellular dysfunction underlying this disease. Measuring and tracking oxidative stress in the human brain using Positron Emission Tomography (PET) provides an opportunity for in vivo mechanistic characterisations disease in the human brain, and represents a novel and potentially sensitive approach to addressing the urgent need for pharmacodynamic and treatment monitoring biomarkers for use in clinical trials. The current study aims to investigate 64Cu-ATSM PET as a tool for imaging oxidative stress in the brains of individuals with FA.

In today's society, snacking has become a regular activity that is affecting the food views and lifestyles of many adults. Regular snacking may simply be the way an individual consumes what they require. But others are consuming snacks that are of poor nutritional value and high in sugar and fat. These types of “snack” foods are being consumed more often and these poor eating habits increase the likelihood of weight gain. We hypothesise that it is this type of snacking behaviour that can be targeted to improve weight mangement for those individuals motivated and able to limit the consumption of snack foods.

MenGO is a Phase III open-label randomised control study in gay and bisexual men, comparing the incidence of gonorrhoea infection in those vaccinated with Bexsero® to those who do not receive the vaccine. The study will test the hypotheses that a reduction in number of gonorrhoea infections will be seen following vaccination with Bexero. It will also investigate Bexsero®-induced antibodies that will inform rational novel vaccine design and show that Bexsero® is a safe vaccine for administration in GBM aged 18-50 years.

This is a randomized, non-inferiority, non-blinded, clinical trial with the two treatments StrataXRT and Mepitel Film being compared within each patient. The purpose of this trial is to determine if StrataXRT is as good as Mepitel Film in reducing the severity and duration of radiation-induced dermatitis,

To determine whether a virtual reality (VR) game of snakes can improve the ability of people with convergence problems to converge as compared to conventional clinical method, and whether is can improve the compliance to treatment. Young adults with convergence problems were pseudo-randomly treated with either the VR Snake game or conventional therapy for three 20 minute sessions per week for 6 weeks. Compliance was assessed as time spent completing the training activities.

Administration of antenatal corticosteroids to women prior to preterm birth has been one of the greatest success stories of modern pregnancy and newborn care. Multiple studies have demonstrated a reduction in the rate of breathing problems in newborn babies after this treatment. More recently, several studies have reported benefits when antenatal corticosteroids are given to women who give birth by elective caesarean section after 35 weeks. Elective CS, as opposed to vaginal birth (or even CS in labour) is associated with greater risks of breathing problems in newborn infants and this results in longer hospital stays and separation from the mother. Women with diabetes were specifically excluded from the studies that have demonstrated improvements in the rate of newborn breathing problems, hence, whether these benefits are the same for infants born to women with diabetes is uncertain. Further research in the subgroup of women with diabetes during pregnancy is urgently needed. This study has been designed to determine the feasibility of undertaking a much larger multicentre, randomised, placebo controlled trial to investigate the outcomes for the mother and baby following antenatal administration of corticosteroids within 7 days prior to elective CS in women with pre-gestational or gestational diabetes. A sample size of 2200 participants will be required for the larger trial. In order to determine the feasibility of such a large study and ensure the collection of appropriate outcome data, we are undertaking a smaller pilot feasibility trial to determine patient and clinician acceptability for such a trial.